<DOC>
	<DOCNO>NCT00383721</DOCNO>
	<brief_summary>This randomize , placebo-controlled , parallel-group , multi-site , double-blind study evaluate efficacy mometasone furoate/formoterol fumarate ( MF/F ) meter dose inhaler ( MDI ) 400/10 mcg twice daily ( BID ) MF/F MDI 200/10 mcg BID compare MF 400 mcg BID F 10 mcg BID adult least 40 year age , moderate severe chronic obstructive pulmonary disease ( COPD ) . All placebo-treated subject active-treated subject participate safety extension discontinue Final Visit Week 26 . Subjects continue 26-week safety extension Final Visit Week 52 . Efficacy measure mean change Baseline Week 13 area force expiratory volume one second concentration time curve 0 12 hour ( FEV1 AUC [ 0-12hr ] ) change Baseline Week 13 AM predose FEV1 .</brief_summary>
	<brief_title>Effects Mometasone Furoate/Formoterol Combination Versus Formoterol Mometasone Furoate Alone Chronic Obstructive Pulmonary Disease ( COPD ) ( Study P04230AM4 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Moderate severe COPD base prebronchodilator FEV1/forced vital capacity ( FVC ) ratio &lt; =70 % . At Screening &amp; Baseline , postbronchodilator FEV1 must &gt; = 60 % predict normal &amp; &gt; =25 % predict normal . COPD symptom &gt; =24 month . &gt; =2 COPD exacerbation require course oral corticosteroid &amp; /or antibiotic within 212 month screen . Ex current smoker smoke history &gt; =10 pack year . Only albuterol/salbutamol relief least 2 week prior randomization . Withdraw parenteral &amp; oral steroid , anticholinergic , &amp; antibiotic 4 week prior Screening . No harm change current COPD therapy , willing discontinue his/her anticholinergic , inhaled corticosteroid ( ICS ) ICS/longacting beta agonist ( LABA ) Screening , &amp; transfer albuterol/salbutamol relief 2 week prior Randomization . Lab test conduct Screening must acceptable investigator . Electrocardiogram ( ECG ) perform Screening within 30 day prior Screening must acceptable investigator . Chest Xray computerize tomography ( CT ) scan acceptable within 12 month prior Screening must acceptable investigator . Female childbearing potential must use birth control . Includes : hormonal contraceptive , intrauterine device ( IUD ) , condom combination spermicide , monogamous relationship male partner vasectomy . Started birth control least 3 month prior Screening ( exception condom ) , &amp; must agree continue . Female currently sexually active must agree/consent use method become sexually active . Women surgically sterilize least 1 year postmenopausal consider childbearing potential . Female must negative serum pregnancy test Screening . Evidence ( upon visual inspection ) oropharyngeal candidiasis Baseline without treatment . If evidence Screening , may treat appropriate &amp; visit schedule upon resolution . If evidence Baseline , may treat appropriate &amp; visit reschedule upon resolution . History renal , hepatic , cardiovascular , metabolic , neurologic , hematologic , ophthalmological , respiratory , gastrointestinal , cerebrovascular , could interfere study require treatment might interfere study . Examples include ( limited ) hypertension treat betablockers ) , active hepatitis , coronary artery disease , arrhythmia , significant QTc prolongation ( ie QTcF QTcB [ Fridericia Bazett correction , respectively &gt; 500 millisecond ( msec ) ] ) stroke , severe rheumatoid arthritis , chronic openangle glaucoma posterior subcapsular cataract , acquire immune deficiency syndrome ( AIDS ) , condition may interfere respiratory function asthma , bronchiectasis , cystic fibrosis . Others wellcontrolled &amp; stable ( eg hypertension require betablockers ) prohibit participation appropriate investigator . Allergy/sensitivity glucocorticosteroids , beta2 agonist , study drug/excipients . Female breastfeeding , pregnant , intend become pregnant . Illicit drug user . Human immunodeficiency virus ( HIV ) positive ( test conduct ) . Unable correctly use oral MDI . Taking restricted medication prior Screening without meet washout . Can adhere permit concomitant &amp; prohibited medication . May participate study another investigational site . Can participate different investigational study site , time . Not randomize study . No person directly associate administration study may participate . Previously participate MF/F trial . Increase absolute volume &gt; =400 milliliter ( mL ) Screening prior Baseline within 30 minute administration 4 inhalation albuterol/salbutamol ( total dose 360 400 mcg ) , nebulized 2.5 mg albuterol/salbutamol . Asthma . Lobectomy , pneumonectomy lung volume reduction surgery . Lung cancer . Requires longterm administration oxygen ( &gt; 15 hours/day ) . Alpha1antitrypsin deficiency . A history and/or presence intraocular pressure either eye &gt; =22 millimeter mercury ( mm Hg ) , glaucoma , and/or posterior subcapsular cataract . A subject undergone incisional intraocular surgery natural lens still present eye . A subject history penetrate trauma eye . A subject one follow Lens Opacities Classification System ( LOCS ) III grade screening : nuclear opalescence ( NO ) : &gt; =3.0 , nuclear color ( NC ) : &gt; =3.0 , cortical cataract ( C ) : &gt; =2.0 , posterior subcapsular ( P ) : &gt; =0.5 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>